Nipro Markets Human iPS Cell Products To Pharmaceutical Companies In Japan
This article was originally published in PharmAsia News
Executive Summary
Japanese drug and device maker Nipro June 1 launched cardiomyocytes made from induced pluripotent stem cells to research institutions and pharmaceutical companies for cardiac research and new drug development. The first commercial products made from human iPS cells in Japan, the cardiomyocytes are manufactured by Tokyo-based biotech venture company ReproCell. Nipro signed a licensing agreement and obtained exclusive rights in Japan. Priced at ¥300,000 each kit consists of five cell clusters, Nipro estimates ¥20-¥50 million in annual sales. The cardiotoxicity assay allows the direct measurement of parameters in an invitro functional assay that comes close to invivo conditions. (Click here for more - Japanese language